Affiliation
CRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.Issue Date
1992
Metadata
Show full item recordAbstract
Interleukin-2 (IL-2) is a cytokine with potent immunomodulating properties which has shown considerable antitumour activity in preclinical models. In clinical trials, the effects of IL-2 given by various routes and schedules have been investigated. IL-2 has been administered either as single drug or in combination with other cytokines and immunomodulating agents, chemo therapeutic agents, or reinfusions of ex vivo activated autologous cytotoxic effector cells. The results of published clinical studies with IL-2 based immunotherapy are reviewed in this paper.Citation
Clinical applications of interleukin-2. 1992, 4 (3):229-46 Prog Growth Factor ResJournal
Progress in Growth Factor ResearchPubMed ID
1307490Type
ArticleLanguage
enISSN
0955-2235Collections
Related articles
- Adoptive immunotherapy of urologic tumors.
- Authors: Belldegrun A, Rosenberg SA
- Issue date: 1989
- Therapy with interleukin-2 and tumor-derived activated lymphocytes.
- Authors: Oldham RK
- Issue date: 1994
- Prospects for gene therapy and lymphokine therapy for metastatic melanoma.
- Authors: Sivanandham M, Scoggin SD, Sperry RG, Wallack MK
- Issue date: 1992 Jan
- [Immunotherapy of malignant melanoma].
- Authors: Flageul B, Miclea JM, Bensussan A, Degos L
- Issue date: 1990 Oct
- [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
- Authors: Barón Saura JM, Pizarro Redondo A, Berrocal Jaime A, González Barón M
- Issue date: 1991 May